* OptimizeRx Corp OPRX.OQ OPRX.O is expected to show a
rise in
quarterly revenue when it reports results on November 13 for
the period ending September 30 2024
* The Waltham Massachusetts-based company is expected to
report a
53.1% increase in revenue to $24.997 million from $16.33 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for OptimizeRx Corp is for
earnings of 6 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for OptimizeRx
Corp
is $15.00, above its last closing price of $5.22.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.06 -0.06 0.02 Beat 131.3
Mar. 31 2024 -0.12 -0.13 -0.11 Beat 13.7
Dec. 31 2023 0.33 0.32 0.26 Missed -19.5
Sep. 30 2023 0.03 0.03 0.09 Beat 260
Jan. -0.02 -0.02 -0.01 Beat 53.3
1 0001
Mar. 31 2023 -0.08 -0.08 -0.09 Missed -12.5
Dec. 31 2022 0.25 0.24 0.25 Beat 3.6
Sep. 30 2022 0.03 0.04 0.07 Beat 90.7
This summary was machine generated November 1 at 14:03 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)